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Aim Despite prompt revascularization of acute myocardial infarction (AMI), substantial myocardial injury may occur, in part a
consequence of ischaemia reperfusion injury (IRI). There has been considerable interest in therapies that may reduce IRI.
In experimental models of AMI, sodium nitrite substantially reduces IRI. In this doubleblind randomized placebo con-
trolled parallel-group trial, we investigated the effects of sodium nitrite administered immediately prior to reperfusion
in patients with acute ST-elevation myocardial infarction (STEMI).
Methods
and results
A total of 229 patients presenting with acute STEMI were randomized to receive either an i.v. infusion of 70 mmol
sodium nitrite (n ¼ 118) or matching placebo (n ¼ 111) over 5 min immediately before primary percutaneous
intervention (PPCI). Patients underwent cardiac magnetic resonance imaging (CMR) at 6–8 days and at 6
months and serial blood sampling was performed over 72 h for the measurement of plasma creatine kinase
(CK) and Troponin I. Myocardial infarct size (extent of late gadolinium enhancement at 6–8 days by CMR-the
primary endpoint) did not differ between nitrite and placebo groups after adjustment for area at risk, diabetes
status, and centre (effect size 20.7% 95% CI: 22.2%, +0.7%; P ¼ 0.34). There were no significant differences
in any of the secondary endpoints, including plasma troponin I and CK area under the curve, left ventricular
volumes (LV), and ejection fraction (EF) measured at 6–8 days and at 6 months and final infarct size (FIS) mea-
sured at 6 months.
Conclusions Sodium nitrite administered intravenously immediately prior to reperfusion in patients with acute STEMI does not reduce
infarct size.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Acute myocardial infarction † Ischaemia-reperfusion injury † Cardioprotection † Nitrite
† D.D., J.C.K., and M.F. are joint senior authors.
* Corresponding author. Tel: +44 1224437965; Fax: + 44 1224437971, Email: m.p.frenneaux@abdn.ac.uk
‡ The list of NIAMI investigators is available in Appendix.
& The Author 2014. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.
permissions@oup.com
European Heart Journal (2014) 35, 1255–1262
doi:10.1093/eurheartj/ehu096
by guest on Decem
ber 18, 2014
D
ow
nloaded from
 
Introduction
Heart failure is a common long-term sequel of acute myocardial in-
farction. While prompt reperfusion in acute STEMI is a pre-requisite
for limiting infarct size, the process of reperfusion itself causes injury
(ischaemia reperfusion injury, IRI) due to opening of the mitochon-
drial permeability transition pore (MPTP) occurring 3 min after
reperfusion.1
Direct ischaemic preconditioning (brief repetitive episodes of
ischaemia and reperfusion prior to a major ischaemic insult)
reduces IRI2 and can be replicated by a variety of pharmacological
agents3 and by remote ischaemic preconditioning.4 In
experimental models, several interventions administered during is-
chaemia or at reperfusion prior to opening of the MPTP (peri and
postconditioning, respectively) have successfully reduced cardiac
IRI.3 A small number of these have been successful in patients with
acute STEMI,5 –8 but several have not.9– 11
Nitrite was in the past considered a relatively inert breakdown
product of nitric oxide (NO), but the last decade has witnessed the
emergence of evidence that nitrite is a bioactive substance with
promising pharmacological properties in its own right. Plasma
nitrite is derived from oxidation of endothelially derived NO12 and
fromthe ingestion of dietary nitratewhich is reduced followingenter-
osalivary circulation to nitrite by oral commensal bacteria.13 In add-
ition to non-enzymatic processes, favoured by hypoxic and acidic
conditions akin to those prevailing in ischaemicmyocardium, multiple
enzymatic processes involving haem and molybdopterine-containing
proteins are thought to be involved in its bioactivation (by reduc-
tion to NO)14 (for detail information, see Supplementary material
online).Nitritehasbeen showntohavevasorelaxant andanti-platelet
properties, that are enhanced by hypoxia.15,16 In a primate model,
there was no evidence of tolerance to the vasorelaxant effects of
sodium nitrite.17 Oral inorganic nitrate supplementation reduces
the oxygen cost of submaximal exercise.18 In experimental models
of AMI, sodium nitrite administered as a pre- or periconditioning
agent has demonstrated very impressive cardioprotection.19–21,22
These effects are seen in the nanomolar concentration range in a
murine model.22 An i.v. infusion of sodium nitrite administered
over the final 5 min of a 120 min coronary occlusion in a canine
model, which resulted in peak plasma levels of5 mmol/L, markedly
reduced IRI.20 In the Nitrites in Acute Myocardial Infarction (NIAMI)
trial, wereplicated the timing, durationand doseof this canine study20
in order toexplore the efficacyof i.v. sodiumnitrite immediatelyprior
to primary percutaneous intervention (PPCI) in patients with STEMI.
We administered the dose of this study on a per kg basis—we there-
foregave 70 mmol nitrite over 5 min, assuming a mean body weight of
70 kg. We previously found that a 5 min infusion of 50 mmol of
sodium nitrite in healthy individuals and patients with heart failure
resulted in a peak concentration of 5 mmol/L.
Methods
Study design
NIAMI, funded by the UK Medical Research Council, was a multicentre,
double-blind, randomized, placebo-controlled trial designed to study
the effect of sodium nitrite administered intravenously over 5 min imme-
diately prior to reperfusion by PPCI on infarct size in patients presenting
with first acute STEMI. The detailed study protocol has been published.23
Regulatory approvals were obtained from Scotland A Research Ethics
Committee and the Medicines and Healthcare products Regulatory
Agency (EudraCT number 2010-023571-26). The study was registered
(NCT01388504, ISRCTN57596739) and overseen by trial steering and
data monitoring committees.23
Patients
We recruited patients from fourcentres (Aberdeen, St Georges Hospital
London and Brighton in the UK and Queen Elizabeth Hospital, Adelaide,
Australia).
Eligiblepatientswere those presenting within12 hof theonsetof chest
pain, with ECG features of first acute STEMI in whom the decision had
been made to proceed with PPCI of the occluded culprit artery, and in
whom TIMI flow was grade 0 or 1. Exclusion criteria included prior MI,
CABG or previous PCI, cardiogenic shock, and contraindication to
CMR.23 Owing to the remote risk of inducing methaemoglobinaemia
in patients with G6PD deficiency, only patients of Northern European
ancestry were recruited.
Consent
Full details of the consent process are reported elsewhere.23 Initial written
consent was obtained where possible, with the majorityof patients provid-
ing verbal agreement. Subsequently, fully informed written consent was
sought.
Randomization
Patients were randomly allocated in a 1 : 1 ratio to active treatment
(70 mmol sodium nitrite in 5 mL water) or matching placebo (5 mL
0.9%saline) usingpermuted blocks. Thedosewasbasedon ananticipated
average patient weight of 70 kg, corresponding to 1 mmol/kg. Technical
aspects of the PCI were left to clinician discretion and all the patients
received dual anti-platelet therapy in accordance with current guidelines.
Scanning
Cardiac magnetic resonance was performed at 6–8 days and at 6 months
using standardized sequences23 and analysed in a single-core laboratory.
Cardiac magnetic resonance was performed at 6–8 days and at 6 months
as published in the study protocol23 using internationally standardized
sequences endorsed by the ESC24 and analysed in a single-core labora-
tory utilizing agreed thresholding and planimetry methods for area at
risk (AAR) and IS.25,26
Blood sampling
Blood samples for the measurement of plasma troponin I and creatine
kinase (CK) were collected prior to, and at 6, 12, 18, 24, 36, 48, 60 and
72 h after injection of the study medication and analysed in Aberdeen
(ultra-Troponin I method on Siemens ADVIACentaur automated immu-
noanalyser and Siemens ADVIA 2400 automated general chemistry ana-
lyser for total CK). In 17 patients, sampling for plasma nitrite was
undertaken prior to infusion and 5 min after completion of the infusion
of study medication and for blood methaemoglobin prior to 10 min
and 2 h after commencing study medication.
Plasma nitrite was measured by high-pressure liquid ion chromatog-
raphy with post-column derivatization using a dedicated analysis
system (ENO-20 with Gilson 234 autoinjector, EPC-500 data processor
and PowerChrome software; Eicom). Plasma was obtained by centrifuga-
tion of EDTA blood within minutes of collection, snap-frozen in liquid
nitrogen and stored at 2808C. Frozen plasma samples were thawed in
the presence of N-ethylmaleimide (10 mM final concentration) and
deproteinized by methanol precipitation immediately prior to analysis.
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Study endpoints
The primary endpoint was the difference in infarct size (expressed as a
percentage of LV myocardial mass) between the active and placebo
groups at 6–8 days post-infarct assessed by the extent of late gadolinium
enhancement (LGE; by planimetry) on CMR.
Secondary endpoints were plasma total CK and troponin I area under
the curve (AUC), infarct size (measured using CMR LGE hyperenhance-
ment extent defined using a cut-off of 5-SD greater than the intensity in
the remote myocardium)27 at 6–8 days with AAR as a covariate (mea-
sured by T2-weighted triple inversion recovery T2-W SPAIR or STIR
with extent determined on the basis of a 2-SD cut-off); LVEF, LV end-
diastolic volume (LVEDV) and LVend-systolic volume (LVESV) measured
by CMR at 6–8 days and at 6 months after AMI; and ‘final’ infarct size (FIS)
(CMR) assessed 6-month post-AMI.
Sample size
The sample size was estimated using simulation methods.23 Based on
data from Botker et al.7 and from our CMR database of patients
studied 1 week following acute STEMI, we assumed the mean infarct
size in the placebo group would be 15–20%, and that a relevant treat-
ment effect would reduce this by 4 absolute percentage points in the
active group. We assumed that the mean AAR was 30% (SD 15) and
the correlation between AAR and infarct size was 0.6. Simulations
showed that 150 participants (75 in each group) were required to
detect the anticipated effect size with 90% power at the 5% alpha level.
In previous published studies of conditioning interventions in acute
STEMI, data loss from randomized patients were high.7 Sample size was
therefore inflated by 30–35% to account for loss of primary
outcome data due to death, contraindication to or failure to proceed
to CMR, or inadequate CMR quality. We planned to recruit between
200 and 210 participants.
Statistical analysis
Baseline and outcome data were described using appropriate sum-
mary measures. The primary outcome was analysed using analysis of
covariance adjusting for AAR, diabetic status, and centre. Secondary
outcomes were analysed using similar models. All analyses were
per-protocol but the sensitivity of the primary outcome and blood
measurement results to missing data were tested using multiple
imputation and missing-not-at-random strategies.28,29 Multiple imput-
ation models were run under the assumption primary outcome data
being missing-at-random (conditional on measured covariates), firstly, a
model including the covariates in the primary analysis strategy listed
above. Secondly, a model that included additional baseline covariates: pre-
vious hypertension, previous angina, hyperlipidaemia, current smoking
status, and sex. This was implemented using Stata’s MI command using
10 imputations. The missing-not-at-random models were implemented
using pattern mixture models which varied the difference delta between
observed and missing data over a range of values of delta from 25% to
+5% FIS. This was done in three ways: delta was equal in both arms;
delta equal to zero in the placebo group only (i.e. no difference between
missing and observed data in placebo group only); finally, delta equal to
zero in the nitrite group only. All analyses were carried out using Stata
13 (StataCorp 2013. Stata Statistical Software: Release 13. College Station,
TX, USA: StataCorp LP).
Results
Characteristics of the study population
As shown in Figure 1 (CONSORT diagram), of 652 patients screened
for eligibility, 372 were deemed at the time by the study team or (out
of hours) by the treating cardiologist to be ineligible and 280 were
randomized and received their allocated intervention. There were
51 of 280 (18%) post-randomization exclusions: in the nitrite
group, there was 1 of 146 (,1%) and in the placebo group, there
were 4 of 134 (3%) participants who did not survive the procedure
or regain capacity and were therefore excluded; 14 of 146 (10%) in
the nitrite group and 8 of 134 (6%) in the placebo group survived
but did not consent to remain in the trial; and finally 13 of 146 (9%)
and 11 of 134 (8%) thought at the time by the treating cardiologist
to be eligible were subsequently found to be ineligible. We therefore
included 229 patients who met the eligibility criteria and who gave
fully informed consent to participate in the trial (118 received
sodium nitrite and 111 placebo). Groups were well balanced for
age, gender, TIMI grade, and pain-to-balloon time (Table 1). All the
patients received the standard dual anti-platelet therapy pre-PCI,
50% received glycoprotein IIb3a inhibitors, and 89% received
heparin pre/during PCI.
Primary outcome
Primary outcome data were obtained from 85 of 118 (72%)
participants in the nitrite and 88 of 111 (79%) in the placebo group.
The reasons for not obtaining primary outcome data were: partici-
pants declining CMR [26 (22%) and 18 (16%) in the nitrite and
placebo groups, respectively] and unreadable scans (12 in total).
The median infarct size was 22% in the nitrite and 20% in the
placebo groups [difference 20.7% (95% CI: 22.2, +0.7; P ¼ 0.30)]
(Table 2). Multiple imputation sensitivity analyses gave similar results
to theprimaryanalysis, the treatmenteffect estimate fromthecompre-
hensive model was20.8% (95% CI:22.3, 0.8; P ¼ 0.34). Results were
robust to missing-not-at-random assumptions for all but implausible
scenarios, for example, delta 25% in the nitrite group but zero in
the placebo group.
Secondary outcomes
Biomarker data for sufficient datapoints to create a 72-h AUC were
available in 158 patients (81 nitrite, 77 placebo). Reasons for incom-
plete biomarker data included participants discharged before 72 h
and patients declining to have (usually nocturnal) samples taken.
Patients with more than two missing datapoints were excluded.
The AUCs for both biomarkers were similar in the two treatment
groups (see Table 2 and Figure 2). The effect size was2125 arbitrary
units (95% CI: 21139, +888 units; P ¼ 0.81) for Troponin I, and
+5766 arbitrary units (95% CI: 28695, +20 288 units; P ¼ 0.79)
for CK. These results were consistent under all sensitivity analyses,
except implausible scenarios.
There was no significant difference in infarct size (5-SD technique)
using AAR (T2) as a covariate between the nitrite and placebo groups
(effect size +0.1% 95% CI 22.5, +2.8; P ¼ 0.92), or in LVEDV,
LVESV or LVEF at 6–8 days, at 6 months or in the changes in these
variables between 6–8 days and 6 months (Table 2).
Final infarct size at 6 months
These data in 118 patients (63 in the nitrite group and 55 in the
placebo group) did not differ significantly between the nitrite and
placebo groups (median 12.0 vs. 14.0%). The effect size was 21.7
(95% CI: 23.2, +5.5; P ¼ 0.19) (Table 2).
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Pre-specified and post hoc subgroup
analysis
In diabetics, there was a treatment effect favouring nitrite,24.5 (95%
CI: 28.8, 20.2; P ¼ 0.041) but not in non-diabetics [20.2 (95%
CI:20.8,1.3);P¼ 0.77].The interactionwasnotsignificant (P¼ 0.067).
There was no interaction between treatment effect and infarct site
(anterior vs. the remainder); in patients with chest pain to PCI times
,120 min vs. the remainder; in those with or without microvascular
obstruction; or those with an AAR of 40% or less vs. more than 40%.
Plasma nitrite measurements
These were performed immediately prior to commencing the study
medication and 5 min after ceasing the study medication in 17
patients (11 nitrite, 6 placebo). Plasma nitrite [mean (SD), mmol/L]
was similar at baseline [0.76 (0.14) vs. 0.73 (0.08)] but higher in the
nitrite group 5 min after ceasing infusion [1.42 (0.96) vs. 0.18
(0.08); P ¼ 0.008]. The fall in the placebo group was not due to haem-
olysis, consistent with nitrite uptake by ischaemic myocardial tissue
or red blood cells.30
Blood methaemoglobin levels
Blood methaemoglobin levels were similar in the nitrite vs. placebo
groups at baseline (0.52+0.08 vs. 0.59+ 0.04%), were higher at
10 min following study medication (0.66+0.12 vs. 0.57+ 0.05;
P ¼ 0.005) and similar in both groups at 2 h.
Safety data
Fifty serious adverse events (SAEs) were recorded in the safety
dataset (280 participants where injection was started). There were
21 events in 19 of 146 participants (13%) in the nitrite group, 29
events in 25 of 134 participants in the (19%) placebo group. There
was one death in the nitrite group and four in the placebo group:
none was related to the study intervention. Therewere no suspected
unexpected serious adverse reactions. Six SAEs were recorded as
‘possibly related’ to the study intervention but were listed in the
protocol as expected events. Two were in the nitrite group and
four in the placebo group.
Discussion
Ischaemia reperfusion injury is a potential target for therapeutic
intervention in acute STEMI. In experimental models, a variety of
pharmacological and non-pharmacological interventions are effect-
ive.3 Periconditioning with remote (limb) ischaemia,7 cyclosporine,5
and exenatide6 have been shown in phase 2 studies to reduce myo-
cardial injury in patients presenting with STEMI. Initial studies sug-
gested a benefit from graded opening of the occluded artery by
repeated balloon inflation (direct postconditioning),8 but this was
not confirmed by a larger study.11 Several other pre, peri, and post-
conditioning interventions have been ineffective in humans.9,10
Sodium nitrite has shown particular efficacy in reducing myocardial
infarct size in experimental models when administered as either a
Figure 1 CONSORT diagram.
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pre or periconditioning agent.19–22 While several different mechan-
isms may contribute to cardioprotection (see Supplementary mater-
ial online, Figure S1), in a murine model of nitrite-mediated cardiac
periconditioning, reduction of nitrite to NO by deoxymyoglobin
appeared to be the dominant mechanism of bioconversion.21
The NO so released S-nitrosylates complex 1 of the electron
transport chain, reducing superoxide production during ischaemia
and reperfusion,31 and thereby reducing opening of the MPTP,
which initiates IRI.
In NIAMI, a 5 min i.v. infusion of sodium nitrite administered to
patients with acute STEMI immediately prior to PPCI did not
reduce infarct size. The findings are consistent for the primary end-
point and for each of the secondary endpoints, and the confidence
intervals clearly exclude the a priori hypothesis.
We replicated the protocol employed in the Gonzalez canine
study20 in which a 5 min infusion of sodium nitrite administered im-
mediately prior to opening of the infarct-related artery substantially
reduced infarct size. In our previous studies in healthy volunteers and
in patients with heart failure given a dose of 50 mmol over 5 min
(vs. 70 mmol over 5 min in NIAMI), peak plasma levels were
5 mmol/L (data not shown), identical to those achieved by the
5 min infusion in the Gonzalez study. The median time to reperfusion
from the onset of infusion in NIAMI was 5 min, coinciding with this
peak level; 5 min after ceasing the infusion (and reperfusion) circulat-
ing nitrite levels were still 1.4 mmol/L in the nitrite group (7.8-fold
higher than in the placebogroup). In apreviousmurinepericondition-
ing study, even doses of sodium nitrite that only increased plasma
levels from 0.7 to 0.9 mmol/L substantially reduced infarct size.22
The question arises whether a higher dose or a longer duration of
infusion might have been effective as both of these strategies would
have resulted in higher plasma nitrite concentrations. In the Gonzalez
study, a 1 h infusion regime resulted in higher plasma levels than the
5 min regime, with significant haemodynamic changes (sometimes
requiring infusion of saline to maintain blood pressure) and a statistic-
ally insignificant incremental reduction in infarct size,20 but we were
concerned about safety in a first-in-disease-area study. The regime
we employed was not associated with hypotension. We cannot
exclude that a benefit might be observed with intracoronary admin-
istration of sodium nitrite. One previous study reported a beneficial
effect of intracoronary administration of sodium nitrite as a precon-
ditioning agent in a swine model.32 A single-centre trial in 80 patients
with acute STEMI in which intra-coronary nitrite was administered at
reperfusion has been completed, and the results are awaited.33
Another important question is whether particular subgroups may
benefit from this intervention. In some previous studies, diabetic
patients have been shown to be relatively resistant to conditioning
agents.34 We therefore pre-specified an analysis according to dia-
betes status. On the contrary, in NIAMI there was a significant treat-
ment benefit in the diabetes subgroup; however, the numbers were
small and the interaction was not significant, therefore, this may well
represent a type 2 error. It has been suggested that patients with
larger infarcts and those reperfused relatively early may gain more
benefit from conditioning strategies.9 In NIAMI, infarct size was rela-
tively large (FIS 15% at 6 months in NIAMI vs. 7% in the placebo group
at 1 month in the AARHUS remote periconditioning study).7 Post hoc
subgroup analysis revealed no interaction for anterior vs. non
anterior infarcts (anterior infarcts tend to be larger), those patients
with larger vs. smaller areas at risk or those with shorter vs. longer
chest pain to reperfusion times. Furthermore, it has been proposed
that patients with totally occluded coronary arteries are more
likely to benefit than those with some flow. Accordingly, our study
included only patients with TIMI 0 or 1 flow, with the vast majority
being 0.
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Table 1 Baseline characteristics
Nitrite
(n5 118)
Placebo
(n5 111)
Age (years) mean (SD) 63 (12) 64 (13)
Female 22 (19) 30 (26)
Weight (kg) median (IQR) 82 (75, 91) 77 (69, 89)
BMI mean (SD) 28 (4) 27 (4)
Previous conditions
Hypertension 35 (30) 35 (32)
hyperlipidaemia 55 (47) 52 (46)
diabetes 14 (12) 19 (17)
Current smoker 53 (45) 47 (42)
Infarct site (ECG)
Anterior 46 (39) 41 (37)
Other sites 72 (61) 70 (63)
Symptom to balloon time (min)
mean (SD) 208 (119) 238 (135)
median (25th, 75th) 164 (127, 256) 203 (133, 317)
TIMI grade pre-PCI
TIMI0 101 (91) 105 (89)
TIMI1 9 (8) 11 (9)
Missing 1 (,1) 2 (2)
Stenting of culprit lesion
by PCI
116 (98) 110 (99)
TIMI grade post-PCI
TIMI0 2 (2) 2 (2)
TIMI1 1 (,1) –
TIMI2 1 (,1) 1 (,1)
TIMI3 112 (95) 107 (96)
Missing 2 (2) 1 (,1)
Other drug therapies pre/during PCI reported to have ‘conditioning’
effects
Nitrates 99 (84) 105 (95)
Morphine 70 (59) 66 (60)
Prior drug therapy
Beta-blocker 12 (10) 6 (5)
Calcium channel blockers 24 (20) 29 (26)
Statins 3 (3) 1 (,1)
Heparin 103 (87) 99 (89)
ACE inhibitors – 1 (0.9)
Nicorandil – –
Allopurinol – –
Data are expressed as number (%) unless otherwise stated. TIMI, thrombolysis in
myocardial infarction; BMI, body mass index kg/m2.
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Organic nitrates confer cardioprotection in experimental
models35 Direct NO donors (and organic nitrates) appear to
exhibit a biphasic dose response as conditioning agents, with lower
doses reducing IRI while higher doses are ineffective.36 However, evi-
dence from clinical studies demonstrating cardioprotection by
organic nitrates is limited.37 Evidence from rodent models suggests
that nitrite mediates the majority of its actions by conversion
to NO.21 In experimental models a biphasic dose–response
relationship is also observed for the cardioprotective effects of
nitrite.22 It is therefore possible that the prior use of organic nitrates,
which apart from NO, also generate nitrite and other NO-related
metabolites during tissue biotransformation33,38 may have already
induced a degree of cardioprotection, thereby limiting the potential
for additional cardioprotection by nitrite. The deleterious effects of
high doses of NO donors and nitrite are likely in part mediated via
the generation of peroxynitrite, which may itself result in IRI.39
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Table 2 Pre-specified primary and secondary outcomemeasures
Measure Nitrite Placebo Effect size (95% CI); P-value
Primary outcome
Infarct size at 6–8 days n ¼ 85 n ¼ 88
Mean (SD) 22.9 (13.5) 23.1 (13.2) 20.7 (22.2, 0.7); 0.30
Median (25th, 75th) 22 (12, 33) 20 (13, 32)
Area at risk
Mean (SD) 33.1 (15.8) 32.4 (14.1)
Median (25th, 75th) 31 (21, 44) 32.5 (22.5, 42)
Secondary outcomes
Troponin AUC n ¼ 81 n ¼ 87
Mean (SD) 3734 (3091) 3807 (3262) 2125 (21139, 888); 0.81
CK AUC n ¼ 81 n ¼ 87
Mean (SD) 67 019 (42 446) 59 574 (48 337) 5766 (28695, 20 288); 0.79
Infarct size 6–8 days (5-SD) n ¼ 82 n ¼ 84
Mean (SD) 14.5 (10.5) 14.7 (11.2) 0.1 (22.5, 2.8); 0.92
Median (25th, 75th) 12 (6, 20) 11.5 (7, 22)
Area at risk (T2) n ¼ 39 n ¼ 46
Mean (SD) 36.1 (24.8) 38.1 (16.9)
Median (25th, 75th) 33 (19, 46) 39 (26 ,51)
Final infarct size at 6 months n ¼ 63 n ¼ 55 21.7 (23.2, 5.5); 0.19
Mean (SD) 13.3 (8.7) 15.0 (9.7)
Median (25th, 75th) 12 (7, 17) 14 (8, 20)
LVEDV (mL) at 6–8 days n ¼ 75 n ¼ 84 23.5 (216.3, 9.2); 0.58
Mean (SD) 159 (41) 162 (40)
LVEDV (mL) at 6 months n ¼ 64 n ¼ 54
Mean (SD) 159 (42) 165 (37) 25.0 (219.8, 9.8); 0.50
LVEDV (mL) (delta) n ¼ 63 n ¼ 51
Mean (SD) 21 (29) 23 (32) 1.3 (210.1, 12.6); 0.82
LVESV (mL) at 6–8 days n ¼ 75 n ¼ 84
Mean (SD) 85 (36) 85 (32) 0.5 (210.4,11.3); 0.93
LVESV (mL) at 6 months n ¼ 64 n ¼ 54
Mean (SD) 75 (31) 78 (28) 22.7 (213.7,8.3); 0.63
LVDV mL (delta) n ¼ 63 n ¼ 63
Mean (SD) 9 (25) 6 (24) 2.0 (27.2, 11.2); 0.66
LVEF % at 6–8 days n ¼ 75 n ¼ 84
Mean (SD) 48 (11) 50 (18) 22.3 (27.1, 2.4); 0.34
LVEF % at 6 months n ¼ 64 n ¼ 54
Mean (SD) 53 (9) 53 (9) 20.6 (23.9, 2.7); 0.72
LVEF % (delta) n ¼ 63 n ¼ 51
Mean (SD) 25 (8) 23 (22) 21.7 (27.6, 4.2); 0.57
Pre-specified primaryand secondary outcome measures. LVEDV, LV, end-diastolic volume; LVESV, LVend-systolic volume; LVEF, LVejection fraction;Delta, Change betweenfirst and
second scan.
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Furthermore, nitroglycerine causes increased electron leak from
complex 1 and complex 11 of the electron transport chain that
appears to be involved in the induction of second window precondi-
tioning,40 but in contrast when nitrite is administered as a pericondi-
tioning agent on a background of organic nitrite therapy this could
potentially favour peroxynitrite formation. Almost all of our patients
had received organic nitrates acutely prior to reperfusion (.90% of
whom had received glyceryl trinitrate), reflecting widespread clinical
practice, none was receiving chronic organic nitrate therapy. This
could be an important reason for the discrepancy between the pre-
clinical data and these clinical data. Nevertheless, new therapies need
to be effective when given to patients receiving standard therapy.
Study limitations
Potential limitations of this study are the exclusion of participant’s
post-randomization and the loss of outcome data. There are a
number of reasons why this occurred. The study was performed in
an acute setting in which decisions regarding eligibility had to be
made by the treating clinician very quickly. A small number were sub-
sequently found by the study team to be ineligible. Some patients
declined to give fully informed consent to remain in the study once
they have had a chance to consider their initial decision. Others
died or, having given fully informed consent, later declined to have,
or were unable to complete, the CMR.
Followingpost-randomizationexclusions, data loss for theprimary
endpoint was 24%, which was less than we anticipated in our sample
size calculations. Compared with similar studies, data loss was
modest. For example, in the AARHUS study the primary endpoint
was the salvage index; 333 patients received the intervention; after
post-randomization exclusions, 251 patients were deemed eligible
for data analysis, and of this subgroup only 142 (57%) contributed
data to this primary endpoint.7
The results of the main analysis were maintained in all sensitivity
analyses except implausible scenarios (i.e. all missing data in the
nitrite group had smaller infarct size but all missing in the placebo
group had larger infarct size). Furthermore, there was significant
loss of serial biomarker data over 72 h that would have compromised
the AUC measurements principally due to patient refusal (usually for
nocturnal samples) or early discharge before 72 h. These patients
were not included in the biomarker analysis. Biomarker results
were robust to sensitivity analysis.
Conclusions
This multi-centre, randomized, double-blind, placebo-controlled
phase 2 trial showed that nitrite was ineffective when administered
intravenously immediately prior to PPCI in patients presenting with
first acute STEMI.
Figure2 Relation between infarct size (late gadolinium enhance-
ment planimetry on early scan) and area at risk (late gadolinium en-
hancement endocardial surface area (ESA) technique on early scan)
in nitrite and placebogroups (upperpanel). Serial measuresof mean
total creatine kinase and Troponin I immediately prior to and over
72 h following administration of nitrite and placebo. Nitrite did not
significantly reduce the area under the curve for either biomarker
(lower panel).
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Table 3 Pre-specified and post hoc subgroup analyses
Effect size (95% CI); P-value
Pre-specified subgroups
Non-diabetics 20.2 (21.8, 1.3); 0.77
Diabetics 24.5 (28.8, 20.2); 0.041
Interaction 24.3 (28.9, 0.3); 0.067
Post hoc subgroups
No microvascular obstruction 20.6 (23.3, 2.1); 0.54
Microvascular obstruction 20.7 (23.4, 1.9); 0.47
Interaction 20.1 (23.9, 3.7); 0.94
Anterior 21.9 (25.1, 1.4); 0.13
Other site 0.0 (22.4, 2.4); 0.97
Interaction 21.9 (25.9, 2.2); 0.24
Late PCI 21.7 (23.8, 0.5); 0.045
Early PCI 2.9 (21.3, 7.1); 0.070
Interaction 4.6 (20.1, 9.3); 0.012
AAR ≤40% 21.2 (25.3, 3.0); 0.46
AAR .40% 22.6 (28.7, 3.5); 0.27
Interaction 21.4 (28.8, 6.0); 0.62
All post hoc subgroup models corrected for AAR except the model exploring the
40% or less vs. more than 40% subgroup analysis which re-expressed AAR as a
dichotomy and therefore did not include the AAR covariate. Late/early PCI, primary
PCI performed after/before the median chest pain to PCI time (120 min); AAR ≤ or
.40%, treatment effect in patients with area at risk≤40% or.40% of LV mass using
LGE ESA measurement on early scan.
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Supplementary material
Supplementary material is available at European Heart Journal online.
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